Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation

Clinical Pharmacokinetics
Christine E Staatz, Susan E Tett

Abstract

The aim of this review is to analyse critically the recent literature on the clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients. Dosage and target concentration recommendations for tacrolimus vary from centre to centre, and large pharmacokinetic variability makes it difficult to predict what concentration will be achieved with a particular dose or dosage change. Therapeutic ranges have not been based on statistical approaches. The majority of pharmacokinetic studies have involved intense blood sampling in small homogeneous groups in the immediate post-transplant period. Most have used nonspecific immunoassays and provide little information on pharmacokinetic variability. Demographic investigations seeking correlations between pharmacokinetic parameters and patient factors have generally looked at one covariate at a time and have involved small patient numbers. Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations, diurnal rhythm, food administration, corticosteroid dosage, ...Continue Reading

References

Oct 1, 1977·Journal of Pharmacokinetics and Biopharmaceutics·L B SheinerV V Marathe
Jun 1, 1992·Clinical Pharmacokinetics·A H Thomson, B Whiting
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A T FojoI Pastan
Nov 1, 1989·Archives of Biochemistry and Biophysics·J D SchuetzP S Guzelian
Jun 1, 1988·Journal of Clinical Pharmacology·M L HuangT E Starzl
Oct 27, 1994·The New England Journal of Medicine·UNKNOWN U.S. Multicenter FK506 Liver Study Group
Jan 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W J SandbornR H Wiesner
Apr 1, 1995·Journal of the American College of Cardiology·J M SwensonJ M Armitage
Mar 1, 1995·Clinical Pharmacology and Therapeutics·W J JuskoQ A Mekki
May 1, 1995·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Winkler, U Christians
Jul 15, 1995·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·P A KellyR Venkataramanan
Aug 1, 1995·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·D Ellis
Feb 1, 1993·Transplantation·S UemotoK Ozawa
Jul 1, 1993·Journal of Clinical Pharmacology·A B JainR Venkataramanan
Dec 1, 1993·Transplantation·Y IwakiB Griffith
Feb 26, 1993·Journal of Immunological Methods·T JungC Rieger
Dec 1, 1995·Therapeutic Drug Monitoring·A W ThomsonA Zeevi
Dec 1, 1995·Therapeutic Drug Monitoring·W J Jusko
Dec 1, 1995·Therapeutic Drug Monitoring·P McMasterA D Mayer
Dec 1, 1995·Therapeutic Drug Monitoring·W J JuskoR Lieberman
Mar 15, 1996·Transplantation·P McShane
Dec 1, 1995·Clinical Pharmacokinetics·R VenkataramananT Starzl
Mar 1, 1996·British Journal of Clinical Pharmacology·U ChristiansK F Sewing
Feb 1, 1996·Clinical Pharmacokinetics·S M Tsunoda, F T Aweeka

❮ Previous
Next ❯

Citations

Feb 20, 2010·European Journal of Drug Metabolism and Pharmacokinetics·Masaki SumiAkira Yamaji
Oct 12, 2012·European Journal of Clinical Pharmacology·Michael A TortoriciAlain Patat
Apr 17, 2013·European Journal of Clinical Pharmacology·V Guy-ViterboFlora Tshinanu Musuamba
Mar 2, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Lennaert C P BorraTeun van Gelder
Aug 8, 2013·Pharmacogenetics and Genomics·Julia M BarbarinoRuss B Altman
Sep 8, 2012·Transplantation·Gerben A J van BoekelLuuk B Hilbrands
Nov 3, 2009·American Journal of Respiratory Cell and Molecular Biology·Tobias DeuseSonja Schrepfer
Sep 8, 2009·BMC Clinical Pharmacology·Gunar StemerRosa Lemmens-Gruber
Jul 3, 2007·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Masahide Fukudo
Jan 5, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Keiko UchidaKosaku Nitta
Sep 19, 2009·Journal of the American Society of Nephrology : JASN·Maarten NaesensDirk R J Kuypers
Sep 21, 2005·Journal of Periodontology·Luís Carlos SpolidorioMarcelo Nicolás Muscará
Dec 12, 2012·Pharmacogenomics and Personalized Medicine·Hamid Abboudi, Iain Am Macphee
Jul 26, 2005·Drugs & Aging·Christine E Staatz, Susan E Tett
Aug 21, 2009·Clinical Pharmacokinetics·Caroline Monchaud, Pierre Marquet
Aug 25, 2011·Drugs·Katherine A BarracloughChristine E Staatz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.